DK2927691T3 - Biomarkører til vurdering af HIV - Google Patents

Biomarkører til vurdering af HIV Download PDF

Info

Publication number
DK2927691T3
DK2927691T3 DK14001259.2T DK14001259T DK2927691T3 DK 2927691 T3 DK2927691 T3 DK 2927691T3 DK 14001259 T DK14001259 T DK 14001259T DK 2927691 T3 DK2927691 T3 DK 2927691T3
Authority
DK
Denmark
Prior art keywords
hiv
total amount
metabolites
tof
fatty acid
Prior art date
Application number
DK14001259.2T
Other languages
English (en)
Inventor
Cotrim Guerreiro Da Silva Ismael Dale
Lo Turco Edson Guimaraes
Diaz Ricoardo Soubie
Therese Koal
Original Assignee
Idcgs Clinica De Diagnosticos Medicos
Centro De Genomas
Biocrates Life Sciences Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idcgs Clinica De Diagnosticos Medicos, Centro De Genomas, Biocrates Life Sciences Ag filed Critical Idcgs Clinica De Diagnosticos Medicos
Application granted granted Critical
Publication of DK2927691T3 publication Critical patent/DK2927691T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Claims (7)

1. Anvendelse af en kombination af metabolitter indeholdt i en blodprøve, omfattende mindst forholdet mellem den totale mængde arachidoniske flerumættede etherlipider (PUFA ae) og den totale mængde monoumættede fedtsyreetherlipider (MUFA ae) samt forholdet mellem den totale mængde monoumættede fedtsyreetherlipider (MUFA ae) og den totale mængde mættede fedtsyrer (SFA) som et biomarkørsæt til overvågning af hiv-sygdomsaktivitet hos et pattedyr.
2. En fremgangsmåde til overvågning af hiv-sygdomsaktivitet hos et pattedyr, hvilken fremgangsmåde omfatter måling i en blodprøve udtaget fra pattedyret af mindst forholdet mellem den totale mængde arachidoniske flerumættede etherlipider (PUFA ae) og den totale mængde monoumættede fedtsyreetherlipider (MUFA ae) samt forholdet mellem den totale mængde monoumættede fedtsyreetherlipider (MUFA ae) og den totale mængde mættede fedtsyrer (SFA).
3. Fremgangsmåde ifølge krav 2, der yderligere omfatter måling af mængden af mindst et acylcarnitin og/eller måling af mængden af mindst en sphingomyelin.
4. Fremgangsmåde ifølge krav 3, hvor den mindst ene acylcarnitin er valgt blandt dem, der er indeholdt i tabel 2 i beskrivelsen, og/eller den mindst ene sphingomyelin er valgt blandt dem, der er indeholdt i tabel 4 i beskrivelsen.
5. Fremgangsmåde ifølge et hvilket som helst af kravene 2 til 4, hvor måling er baseret på en kvantitativ analytisk metode, fortrinsvis kromatografi, spektroskop! og masses pektrometri.
6. Fremgangsmåde ifølge krav 5, hvor kromatografi omfatter GC, CE, LC, HPLC og UHPLC; spektroskopi omfatter UV/Vis, IR og NMR; og masseanalysatorer/spektrometri omfatter ESI eller APCI-QqQ, ESI eller APCI-QqTOF, MALDI-QqQ, MALDI-QqTOF og MALDI-TOF-TOF.
7. Fremgangsmåde ifølge krav 6, hvor masseanalysatorer/spektrometri omfatter Quadrupole Mass Analyzer, Ion Trap Mass Analyzers, TOF (Time of Flight) Mass Analyzer, Orbitrap mass analyser, Magnetic Sector Mass Analyzer, Electrostatic Sector Mass Analyzer, Ion Cyclotron Resonance (ICR) og kombinationer af masseanalysatorer, herunder single quadrupole (Q) og triple quadrupole (QqQ), QqTOF, TOF-TOF, Q-Orbitrap.
DK14001259.2T 2014-04-04 2014-04-04 Biomarkører til vurdering af HIV DK2927691T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14001259.2A EP2927691B1 (en) 2014-04-04 2014-04-04 Biomarkers for assessing HIV

Publications (1)

Publication Number Publication Date
DK2927691T3 true DK2927691T3 (da) 2017-10-30

Family

ID=50488967

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14001259.2T DK2927691T3 (da) 2014-04-04 2014-04-04 Biomarkører til vurdering af HIV

Country Status (9)

Country Link
US (2) US10054604B2 (da)
EP (2) EP2927691B1 (da)
BR (2) BR112016023170B1 (da)
CA (1) CA2944389A1 (da)
DK (1) DK2927691T3 (da)
ES (2) ES2644334T3 (da)
PT (1) PT2927691T (da)
SG (2) SG10201800570RA (da)
WO (1) WO2015150360A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3018289A1 (en) * 2016-05-24 2017-11-30 Excision Biotherapeutics, Inc. Metabalomics and viral diagnostics suite
US11181512B2 (en) 2018-04-16 2021-11-23 Chinese Academy Of Inspection And Quarantine Electronic ID database and detection method for pesticide compounds in edible Agro-products based on GC-Q-Orbitrap
WO2019200947A1 (zh) * 2018-04-16 2019-10-24 中国检验检疫科学研究院 基于LC-Q-Orbitrap的食用农产品中农药化合物电子身份数据库及检测方法
WO2019200946A1 (zh) * 2018-04-16 2019-10-24 中国检验检疫科学研究院 基于GC-Q-Orbitrap的食用农产品中农药化合物电子身份数据库及检测方法
EP3623813A1 (en) * 2018-09-17 2020-03-18 Institut d'Investigació Sanitària Pere Virgili Methods for the prognosis of hiv-infected subjects

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464740A (en) * 1992-09-08 1995-11-07 Amur Research Corp. Diagnositc agent and methods for identifying HIV infected individuals and monitoring their therapy
EP2284540A1 (en) * 2009-07-31 2011-02-16 BIOCRATES Life Sciences AG Method of diagnosing organ failure

Also Published As

Publication number Publication date
US20170184619A1 (en) 2017-06-29
US20170160246A1 (en) 2017-06-08
EP2927691B1 (en) 2017-07-19
EP3126841A1 (en) 2017-02-08
US10725056B2 (en) 2020-07-28
EP2927691A1 (en) 2015-10-07
BR112016023170B1 (pt) 2023-12-12
BR112016023170A2 (pt) 2017-10-10
EP3126841B8 (en) 2019-09-11
US10054604B2 (en) 2018-08-21
PT2927691T (pt) 2017-10-27
SG10201800570RA (en) 2018-03-28
WO2015150360A1 (en) 2015-10-08
SG11201608244TA (en) 2016-10-28
ES2644334T3 (es) 2017-11-28
BR122020000253B1 (pt) 2023-12-19
EP3126841B1 (en) 2019-07-03
CA2944389A1 (en) 2015-10-08
ES2749048T3 (es) 2020-03-18

Similar Documents

Publication Publication Date Title
US20210190785A1 (en) Biomarkers for Assessing Breast Cancer
US10725056B2 (en) Biomarkers for assessing HIV
US20190072569A1 (en) Biomarkers of autism spectrum disorder
ES2825105T3 (es) Obtención del perfil bioquímico de moléculas pequeñas de sujetos individuales para el diagnóstico de enfermedad y evaluación de la salud
JP2015231392A (ja) 自閉症の代謝バイオマーカー
Afshinnia et al. Lipidomics and biomarker discovery in kidney disease
Yunus et al. Pilot study of newborn screening of inborn error of metabolism using tandem mass spectrometry in Malaysia: outcome and challenges
Li et al. Urinary metabolomics revealed arsenic exposure related to metabolic alterations in general Chinese pregnant women
JP2014521928A (ja) アルツハイマー病のリスクの増加を診断するための方法
US20190178900A1 (en) Autism subsets
Costanzo et al. Targeted metabolomics
WO2018191866A1 (zh) 2型糖尿病标志物及其用途
Nyström et al. Mucosal and plasma metabolomes in new-onset paediatric inflammatory bowel disease: Correlations with disease characteristics and plasma inflammation protein markers
Lin et al. Metabolome-wide association study of multiple plasma metals with serum metabolomic profile among middle-to-older-aged Chinese adults
Jones et al. A vision for exposome epidemiology: The pregnancy exposome in relation to breast cancer in the Child Health and Development Studies
CA3157694A1 (en) Diagnosis and treatment of autism spectrum disorders using altered ratios of metabolite concentrations
KR20200013839A (ko) 간헐적 단식 예후 분석을 위한 바이오마커
US20230417774A1 (en) Method for detecting mild cognitive impairment and mild alzheimer's disease
Zharmakhanova et al. Selective screening for inborn errors of metabolism using tandem mass spectrometry in West Kazakhstan children: study protocol
Johnson Aging and the Plasma Metabolome: Relation to Physiological Function
Gonzalez et al. Metabolomics reveals attenuation of the